Clinical observation on 271 cases of non-Small cell lung cancer treated with yifei kangliu yin

Jia-xiang Liu; Zhi-ming Shi; He-gen Li; Zhen-ye Xu; Yan-wei Zhu; Li-hong Zhao; Hong Gao; Ling-shuang Liu; Hui-rong Zhu; Hui Zhang

doi:10.1007/BF02934362

Your Location：

Home >

Browse articles >

Clinical observation on 271 cases of non-Small cell lung cancer treated with yifei kangliu yin

Updated：2021-08-27

- Clinical observation on 271 cases of non-Small cell lung cancer treated with yifei kangliu yin
- Chinese Journal of Integrative Medicine Vol. 7, Issue 4, Pages: 247-250(2001)
- Affiliations：
  
  Department of Tumor, Longhua Hospital, University of Traditional Chinese Medicine and Pharmacology,Shanghai
- Author bio：
- Funds：
- DOI：10.1007/BF02934362
  CLC：
- Published：2001，
Scan for full text
Liu, Jx., Shi, Zm., Li, Hg. et al. Clinical observation on 271 cases of non-Small cell lung cancer treated with yifei kangliu yin., CJIM 7, 247–250 (2001). https://doi.org/10.1007/BF02934362

Jia-xiang Liu, Zhi-ming Shi, He-gen Li, et al. Clinical observation on 271 cases of non-Small cell lung cancer treated with yifei kangliu yin. [J]. Chinese Journal of Integrative Medicine 7(4):247-250(2001)
Liu, Jx., Shi, Zm., Li, Hg. et al. Clinical observation on 271 cases of non-Small cell lung cancer treated with yifei kangliu yin., CJIM 7, 247–250 (2001). https://doi.org/10.1007/BF02934362 DOI：

Jia-xiang Liu, Zhi-ming Shi, He-gen Li, et al. Clinical observation on 271 cases of non-Small cell lung cancer treated with yifei kangliu yin. [J]. Chinese Journal of Integrative Medicine 7(4):247-250(2001) DOI： 10.1007/BF02934362.

摘要

To observe the effects of Yifei Kangliu Yin(YFKLY) in treating non-small cell lung cancer (NSCLC). Two hundred and seventy-one patients with NSCLC were randomly divided into three groups

Group A treated only by YFKLY

Group B treated by the combination of YFKLY and chemotherapy

and Group C treated only by chemotherapy as the control group for control. (1) Of the 127 cases in Group A

1 case got complete remission (CR)

13 got partial remission (PR)

89 had no change (NC)

and 24 had progression of disease (PD)

thus CR+PR+NC accounting for 81.10%

of the 80 patients in Group B

17 got PR

53 got NC

10 got PD

PR+NC accounting for 87.50%

of the 64 cases of chemotherapy group

7 cases got PR

39 cases got NC

18 cases got PD

PR+NC accounting for 71.88% (P<0.01). (2) The metastasis rate was 23.52% in Group A

20.00% in Group B and 35.71% in Group C respectively after treatment. (3) The 1-

3- and 4-year survival rate were 73.09%

32.01%

13.18% and 13.18% in Group A

71.85%

46.35%

29.19% and 23.35% in Group Band 37. 61%

13 67%

9.7% and 0% in Group C. The symptoms were improved

and Kamofsky score was elevated in Group A and B. YFKLY could increase survival rate and quality of life

decrease metastasis rate

and enhance the immune function in NSCLC patients.

Abstract

To observe the effects of Yifei Kangliu Yin(YFKLY) in treating non-small cell lung cancer (NSCLC). Two hundred and seventy-one patients with NSCLC were randomly divided into three groups

Group A treated only by YFKLY

Group B treated by the combination of YFKLY and chemotherapy

and Group C treated only by chemotherapy as the control group for control. (1) Of the 127 cases in Group A

1 case got complete remission (CR)

13 got partial remission (PR)

89 had no change (NC)

and 24 had progression of disease (PD)

thus CR+PR+NC accounting for 81.10%

of the 80 patients in Group B

17 got PR

53 got NC

10 got PD

PR+NC accounting for 87.50%

of the 64 cases of chemotherapy group

7 cases got PR

39 cases got NC

18 cases got PD

PR+NC accounting for 71.88% (P<0.01). (2) The metastasis rate was 23.52% in Group A

20.00% in Group B and 35.71% in Group C respectively after treatment. (3) The 1-

3- and 4-year survival rate were 73.09%

32.01%

13.18% and 13.18% in Group A

71.85%

46.35%

29.19% and 23.35% in Group Band 37. 61%

13 67%

9.7% and 0% in Group C. The symptoms were improved

and Kamofsky score was elevated in Group A and B. YFKLY could increase survival rate and quality of life

decrease metastasis rate

and enhance the immune function in NSCLC patients.

关键词

Yifei Kangliu Yinnon-small cell lung cancertraditional Chinese medical therapy

Keywords

Yifei Kangliu Yinnon-small cell lung cancertraditional Chinese medical therapy

references

Tang ZY. Modern oncology. Shanghai: Publishing House of Shanghai Medical University 1993, 425, 625- 626, 637-638.

Wang RZ, et al. Analysts of effects on NSCLC by different methods. Chin J Radio-Oncology 1995;4(1): 34.

Liu JX. Clinical and experimental research on primary NSCLC in late stage with Fuzheng Method. Prevention of Cancer. Peking: Chinese Scientific and Technological Publishing House 1989:810–8244.

Liu JX. Analysis of the effects of TCM treatment according to Syndrome Differentiation in treating 310 cases of primary NSCLC. Shanghai J TCM 1985; (10) : 3.

FULL TEXT LINK

More>

Views

399

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer

Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine

In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer

Related Author

No data

Related Institution

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute

Department of Oncology, First Affiliated Hospital of Guangzhou University of Chinese Medicine

Guangzhou University of Chinese Medicine

Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine

Department of Oncology, Fuzhou General Hospital, Nanjing Military Command

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰